Figure 6.

Bemarituzumab induces tumor-specific innate and adaptive immune profile changes. Mice bearing 4T1 tumors were treated with 20 mg/kg IP bemarituzumab (Bema), bemarituzumab-N297Q (Bema-N297Q), or human Fc-IgG1 (hFc-G1) on day 0 (when tumors reached approximately 150 mm³) and day 3, and then euthanized 24 hours later on day 4 for immunohistochemistry analysis. Representative fluorescence of NKp46, PD-L1, and CD3-positive T cells (CD3 T cells) 24 hours post second dose of treatment are shown